

## Special Issue

# SARS-CoV-2 Variants: Unraveling Vaccines and Immune Responses

### Message from the Guest Editor

This Special Issue explores the relationship between SARS-CoV-2 variants, vaccine development, and the immune system. We encourage submissions on genomic, molecular, and structural features of SARS-CoV-2 variants and their implications for vaccine effectiveness. We also seek studies on immune response dynamics in the context of these variants. Potential topics of interest include, but are not limited to:

1. Comprehensive characterization of emerging SARS-CoV-2 variants and their unique features;
2. Evaluation of the effectiveness of currently available vaccines against variant strains;
3. Analysis of the immune response elicited by vaccines targeting SARS-CoV-2 variants;
4. Investigation of variant-specific immune evasion mechanisms and their impact on breakthrough infections;
5. Long-term durability and persistence of vaccine-induced immunity against variant strains;
6. Assessment of alternative vaccination strategies or booster doses to address variant challenges;
7. Understanding the implications of SARS-CoV-2 variants on global vaccination efforts and public health interventions;
8. Real-world effectiveness studies of vaccines against variant strains in diverse populations.

---

### Guest Editor

Dr. Zijun Wang

Laboratory of Molecular Immunology, The Rockefeller University, New York City, NY, USA

---

### Deadline for manuscript submissions

closed (31 March 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/176211](https://mdpi.com/si/176211)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).